Case Report: A Patient With COVID-19 Who Benefited From Hemoadsorption

In December 2019, the 2019 novel coronavirus disease (COVID-19), which has been identified to be caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China and spread across the world. Higher plasma levels of cytokines, including interleukin (IL)-6, IL-2, IL-7, IL-10, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Yinke, Qi, Zhipeng, Ma, Jiangwei, Sun, Da, Yao, Li, Xu, Bin, Liu, Wei, Xu, Zhaofa, Deng, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736073/
https://www.ncbi.nlm.nih.gov/pubmed/33335906
http://dx.doi.org/10.3389/fmed.2020.607849
Descripción
Sumario:In December 2019, the 2019 novel coronavirus disease (COVID-19), which has been identified to be caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China and spread across the world. Higher plasma levels of cytokines, including interleukin (IL)-6, IL-2, IL-7, IL-10, and tumor necrosis factor-α, were found in patients with COVID-19, which implies the occurrence of a cytokine storm and its association with disease severity. Extracorporeal blood purification has been proven to effectively remove the released inflammatory cytokines. In this study, we report on a patient with COVID-19 who benefited from hemoadsorption.

Ejemplares similares